甲状腺癌与糖尿病的相关性研究进展

doi:10.16352/j.issn.1001-6325.2022.04.014

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (4): 667-670.doi: 10.16352/j.issn.1001-6325.2022.04.014

甲状腺癌与糖尿病的相关性研究进展

傅菁岚, 邓媛媛, 张颖, 章鑫煦, 陈施静, 刘慧霞^*

中南大学湘雅医院老年内分泌科, 湖南长沙 410008

收稿日期:2021-10-15 修回日期:2022-12-31 出版日期:2022-04-05 发布日期:2022-04-01
通讯作者: * lhx900@aliyun.com
基金资助:
国家自然科学基金(81873672)

Research progress of correlation between thyroid cancer and diabetes mellitus

FU Jing-lan, DENG Yuan-yuan, ZHANG Ying, ZHANG Xin-xu, CHEN Shi-jing, LIU Hui-xia^*

Department of Geriatric Endocrinology, Xiangya Hospital, Central South University, Changsha 410008, China

Received:2021-10-15 Revised:2022-12-31 Online:2022-04-05 Published:2022-04-01
Contact: * lhx900@aliyun.com

摘要/Abstract

摘要： 甲状腺癌(TC)是内分泌系统最常见的恶性肿瘤,糖尿病(DM)是由胰岛β细胞功能障碍或胰岛素抵抗所导致的慢性代谢性疾病。近年来,随着TC与DM的患病率明显上升,众多研究表明这两种疾病发生发展之间存在相关性。

关键词: 甲状腺癌, 糖尿病, 降糖药

Abstract: Thyroid cancer (TC) is the most common malignant tumor of the endocrine system. Diabetes mellitus (DM) is a chronic metabolic disease caused by pancreatic β-cell dysfunction or insulin resistance. In recent years, with the increased morbidity of TC and DM , many studies have shown potential relationship between the occurrence and development of these two diseases.

Key words: thyroid cancer, diabetes mellitus, hypoglycemic drugs

中图分类号:

R736.1

傅菁岚, 邓媛媛, 张颖, 章鑫煦, 陈施静, 刘慧霞. 甲状腺癌与糖尿病的相关性研究进展[J]. 基础医学与临床, 2022, 42(4): 667-670.

FU Jing-lan, DENG Yuan-yuan, ZHANG Ying, ZHANG Xin-xu, CHEN Shi-jing, LIU Hui-xia. Research progress of correlation between thyroid cancer and diabetes mellitus[J]. Basic & Clinical Medicine, 2022, 42(4): 667-670.

参考文献

[1] Kim J, Gosnell JE, Roman SA. Geographic influences in the global rise of thyroid cancer[J]. Nat Rev Endocrinol, 2020, 16: 17-29.
[2] Aschebrook-Kilfoy B, Sabra MM, Brenner A, et al. Diabetes and thyroid cancer risk in the National Institutes of Health-AARP Diet and Health Study[J]. Thyroid, 2011, 21: 957-963.
[3] Linkeviciute-Ulinskiene D, Patasius A, Zabuliene L, et al. Increased risk of site-specific cancer in people with type 2 diabetes: anational cohort study[J]. Int J Environ Res Public Health, 2019, 17: 246.doi:10.3390/ijerph17010246.
[4] Zubcic Z, Sestak A, Mihalj H, et al. The association between type 2 diabetes mellitus, hypothyroidism, and thyroid cancer[J]. Acta Clin Croat, 2020, 59: 129-135.
[5] 邓媛媛,柯飒,刘慧霞,等.甲状腺癌合并糖尿病患者的临床病理特征分析[J].中国普通外科杂志,2020,29:565-573.
[6] Zhang X, Sheng X, Miao T, et al. Effect of insulin on thyroid cell proliferation, tumor cell migration, and potentially related mechanisms[J]. Endocr Res, 2019, 44: 55-70.
[7] Zhao J, Wen J, Wang S, et al. Association between adipokines and thyroid carcinoma: a meta-analysis of case-control studies[J]. BMC Cancer, 2020, 20: 788.doi: 10.1186/s12885-020-07299-x.
[8] Zhang G, Jiao Q, Shen C, et al. Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer[J]. Cancer Sci, 2021, 112: 997-1010.
[9] Liotti F, Collina F, Pone E, et al. Interleukin-8, but not the related chemokine CXCL1, sustains an autocrine circuit necessary for the properties and functions of thyroid cancer stem cells[J]. Stem Cells, 2017, 35: 135-146.
[10] Yaribeygi H, Sathyapalan T, Atkin SL, et al. Molecular mechanisms linking oxidative stress and diabetes mellitus[J]. Oxid Med Cell Longev, 2020, 2020: 8609213.doi:10.1155/2020/8609213.
[11] Tabur S, Aksoy SN, Korkmaz H, et al. Investigation of the role of 8-OHdG and oxidative stress in papillary thyroid carcinoma[J]. Tumour Biol, 2015, 36: 2667-2674.
[12] Zhang Z, Xu T, Qin W, et al. Upregulated PTPN2 induced by inflammatory response or oxidative stress stimulates the progression of thyroid cancer[J]. Biochem Biophys Res Commun, 2020, 522: 21-25.
[13] Elgazar EH, Esheba NE, Shalaby SA, et al. Thyroid dysfunction prevalence and relation to glycemic control in patients with type 2 diabetes mellitus[J]. Diabetes Metab Syndr, 2019, 13: 2513-2517.
[14] Schiffmann L, Kostev K, Kalder M. Association between various thyroid gland diseases, TSH values and thyroid cancer: a case-control study[J]. J Cancer Res Clin Oncol, 2020, 146: 2989-2994.
[15] Song YS, Kim MJ, Sun HJ, et al. Aberrant thyroid-stimulating hormone receptor signaling increases VEGF-A and CXCL8 secretion of thyroid cancer cells, contributing to angiogenesis and tumor growth[J]. Clin Cancer Res, 2019, 25: 414-425.
[16] Zou M, Baitei EY, Al-Rijjal RA, et al. TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via down-regulation of p53 expression in papillary thyroid cancer[J]. Oncogene, 2016, 35: 1909-1918.
[17] Bidulescu A, Dinh PC, Sarwary S, et al. Associations of leptin and adiponectin with incident type 2 diabetes and interactions among African Americans: the Jackson heart study[J]. BMC Endocr Disord, 2020, 20: 31. doi:10.1186/s12902-020-0511-z.
[18] Cheng SP, Yin PH, Chang YC, et al. Differential roles of leptin in regulating cell migration in thyroid cancer cells[J]. Oncol Rep, 2010, 23: 1721-1727.
[19] Dossus L, Franceschi S, Biessy C, et al. Adipokines and inflammation markers and risk of differentiated thyroid carcinoma: the EPIC study[J]. Int J Cancer, 2018, 142: 1332-1342.
[20] Ye J, Qi L, Chen K, et al. Metformin induces TPC-1 cell apoptosis through endoplasmic reticulum stress-associated pathways in vitro and in vivo[J]. Int J Oncol, 2019, 55: 331-339.
[21] Cho YY, Kang MJ, Kim SK, et al. Protective effect of metformin against thyroid cancer development: apopulation-based study in Korea[J]. Thyroid, 2018, 28: 864-870.
[22] Li C, Kuang J, Zhao Y, et al. Effect of type 2 diabetes and antihyperglycemic drug therapy on signs of tumor invasion in papillary thyroid cancer[J]. Endocrine, 2020, 69: 92-99.
[23] Kebebew E, Lindsay S, Clark O, et al. Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer[J]. Thyroid, 2009, 19: 953-956.
[24] Tseng C. Rosiglitazone may reduce thyroid cancer risk in patients with type 2 diabetes[J]. Ann Med, 2013, 45: 539-544.
[25] Chen JY, Wang JJ, Lee HC, et al. Combination of peroxisome proliferator-activated receptor gamma and retinoid X receptor agonists induces sodium/iodide symporter expression and inhibits cell growth of human thyroid cancer cells[J]. J Chin Med Assoc, 2020, 83: 923-930.

甲状腺癌与糖尿病的相关性研究进展

Research progress of correlation between thyroid cancer and diabetes mellitus

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李耀洋, 王书宇, 杨丹, 吴群励. 梁晓春教授治疗糖尿病肾脏病的用药经验[J]. 基础医学与临床, 2024, 44(9): 1335-1340.
[2]	彭晴怡, 许岭翎. 1型糖尿病诱发肌少症的研究进展[J]. 基础医学与临床, 2024, 44(8): 1189-1193.
[3]	王泽颖, 刘治, 邰玉, 杨忠彬, 苏燕. 转酮醇酶在糖尿病及其并发症发生和治疗中作用的研究进展[J]. 基础医学与临床, 2024, 44(7): 1023-1028.
[4]	齐梦亚, 李玉秀, 余洁, 张化冰, 许翎岭, 李伟, 平凡. 新确诊糖尿病患者增加运动与降低胰岛素抵抗和心血管危险因素相关[J]. 基础医学与临床, 2024, 44(7): 984-988.
[5]	刘潇, 王曌慧, 魏心怡, 周玥, 赵丽, 王玥, 李俊发. 糖尿病合并TREM2突变相关认知功能障碍的生物信息学分析[J]. 基础医学与临床, 2024, 44(5): 630-636.
[6]	王瑞, 柒铭铭, 杨微涛, 黄健, 肖锦艳, 李一春, 王永红, 刘燕萍. 综合营养管理对妊娠期糖尿病患者的血糖及妊娠结局的影响[J]. 基础医学与临床, 2024, 44(4): 434-439.
[7]	秦小英, 刘慧, 韩冲芳, 贺建东. 改善昼夜节律紊乱减轻糖尿病大鼠心肌缺血/再灌注损伤[J]. 基础医学与临床, 2024, 44(2): 231-234.
[8]	张雅慧, 白琼. 低氧诱导因子-1α在糖尿病肾病中作用机制的研究进展[J]. 基础医学与临床, 2024, 44(1): 114-118.
[9]	张伟才, 刘肆仁, 王尚农. 硫氢化钠增加高糖高脂条件下小鼠心房肌细胞系HL-1谷胱甘肽合成[J]. 基础医学与临床, 2024, 44(1): 69-76.
[10]	田亚婷, 张芳, 张博翔, 李甜. 马里苷减轻糖尿病小鼠心肌纤维化[J]. 基础医学与临床, 2024, 44(1): 51-56.
[11]	王丽婷, 许岭翎, 李伟, 平凡, 张化冰, 马亚红, 李玉秀. 不同亚型1型糖尿病患者大血管病变临床特征及危险因素分析[J]. 基础医学与临床, 2023, 43(8): 1284-1288.
[12]	吴智钢, 权冬, 常欣, 陈雪雪, 张子茹. 富血小板血浆加速糖尿病大鼠骨损伤愈合[J]. 基础医学与临床, 2023, 43(8): 1193-1200.
[13]	王鑫瑞, 秦燕. Ghrelin在代谢性疾病中作用的研究进展[J]. 基础医学与临床, 2023, 43(8): 1299-1303.
[14]	刘充, 刘迎迎, 郭兆安. 特异性促炎消退介质在糖尿病肾脏疾病中的研究进展[J]. 基础医学与临床, 2023, 43(7): 1152-1156.
[15]	陈纤纤, 冯烈, 周颖, 董向楠. 糖尿病肾病与其他类型肾病患者肾组织中Smad1蛋白表达的比较[J]. 基础医学与临床, 2023, 43(7): 1097-1103.